Swings to profit. Ovid Therapeutics Inc. (NASDAQ: OVID) reported Q4 2025 GAAP EPS of $0.06. The biotechnology company swung to profitability from a year-ago loss of $0.13 per share. Net income reached $9.7 million for the quarter.
Revenue climbs sharply. Q4 revenue of $718,000 exceeded the consensus estimates and increased sharply from $76,000 reported in Q4 2024. The trading volume surged to 35.9 million shares as the stock closed at $2.01, near its 52-week high of $2.50. The company maintains unanimous Buy ratings from all 11 covering analysts.
This article was generated using AlphaStreet’s proprietary financial analysis technology and reviewed by our editorial team.
The post Ovid Therapeutics (OVID) Swings to $0.06 EPS in Q4 FY25 first appeared on Alphastreet.
